Which statement about hyperthyroidism is false? A) It is characterized by low thyroid‑stimulating hormone (TSH) with elevated triiodothyronine (T3) and thyroxine (T4) levels; B) Symptoms include tachycardia, resting tremor, and sweating; C) It may be diagnosed after the initial diagnosis of atrial fibrillation; D) In Graves' disease it is usually accompanied by thyroid gland enlargement; E) It cannot be caused by pharmacological agents.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

The FALSE Statement is E

Statement E is incorrect: hyperthyroidism CAN be caused by pharmacological agents. 1

Analysis of Each Statement

Statement A - TRUE

Hyperthyroidism is indeed characterized by suppressed TSH (<0.01 mU/L) with elevated T3 and T4 levels in overt disease 1. In milder cases, T4 may be normal with only T3 elevated (T3-toxicosis), but TSH remains undetectable 1.

Statement B - TRUE

Tachycardia, resting tremor, and sweating are classic hyperthyroid symptoms resulting from increased adrenergic stimulation and elevated metabolic rate 1. These symptoms are more pronounced in younger patients and those with larger goiters 1.

Statement C - TRUE

Atrial fibrillation is a well-recognized complication of hyperthyroidism, and hyperthyroidism may be diagnosed following the initial presentation with AF 1. Studies show hyperthyroidism is present in approximately 10% of new-onset atrial fibrillation cases 2, and thyroid dysfunction has a prevalence of up to 76% in AF patients 3. Guidelines recommend TSH measurement in all new-onset AF evaluations 4.

Statement D - TRUE

Graves' disease is characteristically associated with diffuse thyroid gland enlargement 1. This distinguishes it from toxic nodular goiter, which presents with nodularity rather than diffuse enlargement.

Statement E - FALSE (The Correct Answer)

This statement is definitively false. Multiple pharmacological agents cause hyperthyroidism:

  • Amiodarone: Causes thyrotoxicosis in 5-10% of treated patients 1
  • Iodine: Can trigger iodine-induced hyperthyroidism, especially in patients with underlying thyroid autonomy 1
  • Lithium: Associated with painless thyroiditis and hyperthyroidism 1
  • Cytokines (e.g., interferon-alpha): Cause cytokine-induced thyrotoxicosis 1

The American Thyroid Association guidelines specifically include entire sections on managing drug-induced thyrotoxicosis, including detailed protocols for iodine-induced, cytokine-induced, and amiodarone-induced thyrotoxicosis 1.

Clinical Pitfall

A common error is assuming hyperthyroidism is always endogenous. Always obtain a medication history when evaluating thyrotoxicosis, particularly checking for amiodarone (cardiac patients), iodine-containing contrast or supplements, lithium (psychiatric patients), and interferon therapy 1.

References

Guideline

hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the american thyroid association and american association of clinical endocrinologists.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

Research

Evaluation of thyroid dysfunction in patients with paroxysmal atrial fibrillation.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2007

Related Questions

How to manage atrial fibrillation in patients with abnormal Thyroid-Stimulating Hormone (TSH) levels?
In a 22-year-old man with suppressed thyroid‑stimulating hormone (TSH) (<0.005 µIU/mL) and symptoms of hyperthyroidism, what is the appropriate next step in management?
In a 70-year-old patient with chronic fatigue and a suppressed thyroid-stimulating hormone (TSH) of 0.02 µIU/mL, should hyperthyroidism be managed in primary care or referred to an endocrinologist?
Should thyroid stimulating hormone (TSH) be measured in patients aged 65 or older who present with new‑onset atrial fibrillation?
In an elderly patient with subclinical hyperthyroidism and suppressed TSH who is taking carbimazole 5 mg twice daily, should the carbimazole dose be adjusted?
What are the indications, recommended dosing regimens, and safety considerations for Keflex (cephalexin)?
What are the contraindications for the various birth control methods, including combined oral contraceptives, progestin‑only pills, sub‑dermal implants, depot medroxyprogesterone injection, levonorgestrel intrauterine system, copper intrauterine device, tubal ligation, and barrier methods?
Will removal of the distal colon improve symptoms of irritable bowel syndrome?
What is the appropriate management for a patient with markedly elevated troponin, severe acute kidney injury (creatinine 985.3 µmol/L), and hyperkalaemia (potassium 5.8 mmol/L)?
What is the appropriate evaluation and management for a 66-year-old female with hepatic steatosis and hepatomegaly identified on abdominal ultrasound?
Are there any verified case studies evaluating aged garlic extract in patients with metastatic prostate cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.